SF1126 is a first-in-class, pan and dual PI3K/BRD4 inhibitor developed as an RGDS-conjugated prodrug of LY294002. This design enhances solubility and promotes tumor-targeted delivery via integrin binding. It has demonstrated activity in both in vitro and in vivo cancer models, including studies in multiple myeloma and solid tumors.
Molekulargewicht:
852.84
CAS Nummer:
[936487-67-1]
Formel:
C39H48N8O14
Target-Kategorie:
Others,PI3K,Apoptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
